Advertisement
Canada markets open in 2 hours 46 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7322
    -0.0001 (-0.01%)
     
  • CRUDE OIL

    83.87
    +0.30 (+0.36%)
     
  • Bitcoin CAD

    87,770.10
    +1,054.56 (+1.22%)
     
  • CMC Crypto 200

    1,388.91
    -7.62 (-0.55%)
     
  • GOLD FUTURES

    2,357.80
    +15.30 (+0.65%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,742.75
    +175.25 (+1.00%)
     
  • VOLATILITY

    15.63
    +0.26 (+1.69%)
     
  • FTSE

    8,111.73
    +32.87 (+0.41%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6823
    +0.0002 (+0.03%)
     

Analyst Ratings for Monsanto: A February Update

Analyst Ratings for Monsanto: A February Update

Monsanto (MON), which reported its earnings on January 4, 2018, has risen 2.1%. It’s awaiting a merger with Bayer, which continues to be delayed due to anti-trust concerns from regulators in the European Union and other regions. On February 7, 2018, the merger received approval from Brazilian antitrust regulators. As of February 22, 2018, the consensus mean rating for Monsanto from 18 analysts surveyed by Reuters was 2.6 with an overall “hold” recommendation for the next 12-month period.